Table 2 Demographic and clinical characteristics of patients randomized at Day 2 (included in« blastocyst analysis »).
From: Impact of oxygen tension according to embryo stage of development: a prospective randomized study
Group A 20% O2 (n = 88) | Group B’ 5% O2 (n = 101) | Group C 5–20% O2 (n = 94) | |
|---|---|---|---|
Female age (y) | 32.8 (3.8) | 32.2 (4.6) | 33.3 (4.5) |
Male age (y) | 35.7 (6.0) | 36.2 (6.7) | 37.6 (7.3) |
Female BMI (kg/m2) | 24.9 (4.4) | 25.2 (4.3) | 25.2 (4.6) |
Male BMI (kg/m2) | 26.4 (3.7) | 26.5 (4.6) | 25.4 (4.1) |
Smoking (female), n (%) | |||
Yes | 12 (15.0) | 16 (17.0) | 16 (18) |
Antral follicle count (n) | |||
AMH (ng/mL) | 4.8 (3.3) | 4.8 (4.6) | 5.3 (6.9) |
Day 3 FSH (IU/L) | 6.1 (2.0) | 6.2 (1.6) | 6.0 (1.8) |
Ovarian function, n (%) | |||
Normal | 65 (76.0) | 74 (79.0) | 63 (73) |
Infertility duration (y) | 4.6 (2.3) | 4.9 (2.8) | 4.4 (2.5) |
Cause of infertility, n (%) | |||
Female | 57 (65.0) | 49 (49.0) | 57 (61) |
Male | 24 (27.0) | 39 (39.0) | 33 (35) |
Idiopathic | 16 (18.0) | 22 (22.0) | 14 (15) |
Stimulation protocol (%) | |||
Antagonist | 81 (92.0) | 90 (89.0) | 86 (91) |
Total FSH dose administered (IU) | 2005 (823) | 2348 (1060) | 2351 (1285)* |
Estradiol day hCG (pg/mL) | 2870 (1747) | 2530 (1184) | 2760 (1412) |
Progesterone day hCG (pg/mL) | 0.9 (0.7) | 0.9 (0.5) | 0.8 (0.6) |
Endometrium thickness (mm) | 10.3 (2.4) | 10.6 (2.3) | 11.0 (2.4) |
